MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients

Although imatinib is highly effective in the treatment of chronic myeloid leukemia (CML), 25–30% patients do not respond or relapse after initial response. Imatinib uptake into targeted cells is crucial for its molecular response and clinical effectiveness. The organic cation transporter 1 (OCT1) ha...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Cancer J
Asıl Yazarlar: Harrach, S, Schmidt-Lauber, C, Pap, T, Pavenstädt, H, Schlatter, E, Schmidt, E, Berdel, W E, Schulze, U, Edemir, B, Jeromin, S, Haferlach, T, Ciarimboli, G, Bertrand, J
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2016
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5056971/
https://ncbi.nlm.nih.gov/pubmed/27635733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2016.79
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller